Wednesday, July 8, 2026

biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT

Adaptive Biotechnologies

Adaptive Biotechnologies is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker ADPT. Primary therapeutic focus areas include Post Traumatic Stress Disorder, Prosthetic Joint Infection, O

1165 Eastlake Ave E, Seattle, Washington 98109, US HQ
2009 Founded
659 Employees
Public company Type
ADPT · NYSE Ticker
Company details
Status
Public
HQ
1165 Eastlake Ave E, Seattle, Washington 98109, US
Founded
2009
Employees
659
Programs
19
Drugs
23
Patents
12
Clinical program

Bacteriophage Therapy

Phase 2 · mab · Osteomyelitis

Bacteriophage Therapy for Osteomyelitis is a Phase 2 program (mab) at Adaptive Biotechnologies Corp with 1 ClinicalTrials.gov record(s).

Internal code APT.DFI.001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Adaptive Biotechnologies Corp
Phase
Phase 2
Modality
mab
Indication
Osteomyelitis
Status
terminated
Trials
1

Clinical trials